Results 1 to 10 of about 36,369 (248)

Fosfomycin [PDF]

Clinical Microbiology Reviews, 2016
SUMMARY The treatment of bacterial infections suffers from two major problems: spread of multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens and lack of development of new antibiotics active against such MDR and XDR bacteria.
Matthew E Falagas, George Samonis, Konstantinos Z Vardakas   +2 more
exaly   +6 more sources

The Combination of Daptomycin with Fosfomycin is More Effective than Daptomycin Alone in Reducing Mortality of Vancomycin-Resistant Enterococcal Bloodstream Infections: A Retrospective, Comparative Cohort Study

Infectious Diseases and Therapy, 2023
Introduction High-dose daptomycin-based combinations are recommended for vancomycin-resistant Enterococcus (VRE) bloodstream infection (BSI). Preclinical data have shown a synergistic effect of daptomycin/fosfomycin combinations against VRE.
Tai-Chung Tseng, Yu-Chung Chuang, Jia-Ling Yang, Chi-Ying Lin, Sung-Hsi Huang, Jann-Tay Wang, Yee-Chun Chen, Shan-Chwen Chang   +7 more
doaj   +2 more sources

Inactivation of ackA and pta Genes Reduces GlpT Expression and Susceptibility to Fosfomycin in Escherichia coli

Microbiology Spectrum, 2023
Fosfomycin is used to treat a variety of bacterial infections, including urinary tract infections caused by Escherichia coli. In recent years, quinolone-resistant and extended-spectrum β-lactamase (ESBL)-producing bacteria have been increasing.
Hidetada Hirakawa, Ayako Takita, Yumika Sato, Suguru Hiramoto, Yusuke Hashimoto, Noriyasu Ohshima, Yoji A. Minamishima, Masami Murakami, Haruyoshi Tomita   +8 more
doaj   +2 more sources

In Vitro and In Vivo Synergism of Fosfomycin in Combination with Meropenem or Polymyxin B against KPC-2-Producing Klebsiella pneumoniae Clinical Isolates

Antibiotics, 2023
Fosfomycin disodium is a potential therapeutic option to manage difficult-to-treat infections, especially when combined with other antimicrobials. In this study, we evaluated the activity of fosfomycin in combination with meropenem or polymyxin B against
Aghata Cardoso da Silva Ribeiro, Yohanna Carvalho dos Santos Aoun Chikhani, Tiago Barcelos Valiatti, André Valêncio, Mariana Neri Lucas Kurihara, Fernanda Fernandes Santos, Luciene Andrade da Rocha Minarini, Ana Cristina Gales   +7 more
doaj   +2 more sources

High incidence of fosfomycin-resistant uropathogenic E. coli among children

BMC Infectious Diseases, 2023
Background There are few epidemiological or molecular data on Escherichia coli (E. coli) strains resistant to fosfomycin. In this study, we described the occurrence and characterization of fosfomycin-resistant uropathogenic E.
Wedad M. Abdelraheem, W. K.M Mahdi, Ibtehal S. Abuelela, Noha Anwar Hassuna   +3 more
doaj   +2 more sources

Formulation, development and characterization of fosfomycin tromethamine pessaries for the treatment of vaginal infections [PDF]

Scientific Reports
Background The present study investigated the formulation, development, and characterization of Fosfomycin pessaries for the treatment of genitourinary tract infections. To achieve higher local concentration and to avoid the systemic exposure of the body
Mahboob Ul Haq, Attiqa Naz, Abdul Baseer, Sajjad Ahmad, Basmah F. Alharbi, Muhammad Khurram   +5 more
doaj   +2 more sources

Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial

Nature Medicine, 2023
Treatment failure occurs in about 25% of patients with methicillin-susceptible Staphylococcus   aureus (MSSA) bacteremia. We assessed whether cloxacillin plus fosfomycin achieves better treatment success than cloxacillin alone in hospitalized adults with
, Miquel Pujol Rojo, Joaquin Lopez-Contreras   +2 more
exaly   +2 more sources

Transporter Genes and fosA Associated With Fosfomycin Resistance in Carbapenem-Resistant Klebsiella pneumoniae

Frontiers in Microbiology, 2022
Infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) are of significant clinical concern worldwide. Fosfomycin is one of the limited treatment options for CRKP. However, resistance to fosfomycin in CRKP has been observed. In this study,
Yu-Ping Wang, Yu-Ping Wang, Yu-Ping Wang, Yen-Hao Chen, I-Cheng Hung, Po-Hsun Chu, Yu-Han Chang, Yi-Tsung Lin, Hung-Chih Yang, Hung-Chih Yang, Jin-Town Wang, Jin-Town Wang   +11 more
doaj   +2 more sources

Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem–Resistant Acinetobacter baumannii

Pharmaceuticals, 2021
The spread of multi-drug resistant (MDR) pathogens and the lagging pace in the development of novel chemotherapeutic agents warrant the use of combination therapy as a reliable, cost-effective interim option.
Ozioma F. Nwabor, Pawarisa Terbtothakun, Supayang P. Voravuthikunchai, Sarunyou Chusri   +3 more
doaj   +2 more sources

Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study

Infectious Diseases and Therapy, 2020
Introduction Severe pneumonia caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) remains a difficult-to-treat infection. Considering the poor lung penetration of most antibiotics, the choice of the better antibiotic regimen is debated ...
Alessandro Russo, Matteo Bassetti, Valeria Bellelli, Luigi Bianchi, Federica Marincola Cattaneo, Stefania Mazzocchetti, Elena Paciacconi, Fabrizio Cottini, Arcangelo Schiattarella, Giuseppe Tufaro, Francesco Sabetta, Alessandro D’Avino   +11 more
doaj   +2 more sources